200 articles
What’s changing in cannabis law: our editors’ articles, and announcements straight from regulators, courts, governments and companies.
Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder
Collaboration will increase access to practitioner education in the United States and internationally
Not sure how they can call themselves luminous mind when they are taking away the luminosity.
Our psychedelic and mental health Investment Emyria (ASX: EMD) just opened its Sydney Empax clinic, with first patients already in treatment.
RN Collins has written a new series (3) of 18 articles for cannabis law report on 2026 Psychedelics & Legal Issues.
Female-founded, indoor-grown flower brand enters Europe as SOMAÍ expands its international portfolio of pharmaceutical-grade cannabis medicines
RN Collins has written a new series (3) of 18 articles for cannabis law report on 2026 Psychedelics & Legal Issues.
Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine ( CMND ), spoke on patient access and shared insights from Clearmind’s clinical trial at Yale and Johns Hopkins
The first of two public hearings on proposed rules will begin tonight at 6:00pm (Pacific Time).
Adults looking for legal alcohol alternatives in 2026 can buy hemp-derived THC products, kratom, kava, kanna, and other modern botanicals online from HITT. But “alcohol alternative” is a shopping category, not a legal category.…
Psychedelic-Assisted Therapies Now Reaching Hundreds of Australians as Global Momentum Accelerates
MAPS provided the first outside funding for the University of Miami ibogaine research program in the 1990s
The reported resubmission of the New Drug Application will initiate a new evaluation of the treatment’s safety and efficacy for potential FDA approval
WASHINGTON — The U.S. Department of Veterans Affairs today announced the launch of a new clinical trial to evaluate the effectiveness and safety of psilocybin to treat major depression in Veterans, including those with concurrent…
BOSTON, July 27, 2026 (GLOBE NEWSWIRE) — Rose Hill Life Sciences (“Rose Hill” or “the Company”), a clinical-stage biotechnology company advancing psychedelic therapeutics for neurological and psychiatric conditions, announced the…
Leader Schumer, Sens. Booker, Wyden Reintroduce Legislation To End Federal Ban Of Marijuana
Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025.
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies
Yes as i read my way through this “article” it seemed to me a bit fishy, a thinly veiled press release for Exilby so i thought to myself let’s just ask google which law firm(s) represent Exilby
